Effect of Adaptive Servo Ventilation (ASV) on Survival and Hospital Admissions in Heart Failure
A trial with no phase registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 732 participants.
Also called NCT01128816
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 732 participants
- Registry
-
NCT01128816
-
- Other papers using this trial's data
- Adaptive servo-ventilation for sleep-disordered breathing in patients with heart failure with reduced ejection fraction (ADVENT-HF): a multicentre, multinational, parallel-group, open-label, phase 3 randomised controlled trial
- Nocturnal Cardiac Arrhythmias in Heart Failure With Obstructive and Central Sleep Apnea
- Win Ratio Analysis for Peak-Flow Adaptive Servoventilation in Treating Sleep Apnoea in Heart Failure With Reduced Ejection Fraction
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States, Brazil, Canada, France, Germany, Italy, Japan, Spain, United Kingdom
- Registry status
- Terminated
Technical summary
Registry record NCT01128816. Randomized; no masking; primary purpose treatment. Start 2010-05 (registry gives no type); primary completion 2022-03-31 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effect of Adaptive Servo Ventilation (ASV) on Survival and Hospital Admissions in Heart Failure
- Acronym
- ADVENT-HF
- Condition
- Sleep Apnea
- Condition
- Heart Failure
- Intervention (Device)
- Adaptive Servo Ventilation
- Lead sponsor
- Toronto Rehabilitation Institute
- Collaborator
- Canadian Institutes of Health Research (CIHR)
- Collaborator
- Philips Respironics
Record details
- Record id
cardio:ct-nct01128816- Content hash
e20fbe09d5d3f34550b1ebd093d368e597969e64c817e90f3cfafa3b75793ede